

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



中生北控生物科技股份有限公司
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION
(a joint stock limited company incorporated in the People's Republic of China with limited liability)
(Stock Code: 8247)

FURTHER ANNOUNCEMENT
DISCLOSEABLE TRANSACTION IN RELATION TO
CAPITAL INCREASE AND DEEMED DISPOSAL OF
THE EQUITY INTEREST IN A SUBSIDIARY

Reference is made to the announcement of Biosino Bio-Technology and Science Incorporation (the “**Company**”) dated 18 August 2023 (the “**Announcement**”). Unless otherwise stated, capitalised terms used herein shall bear the same meanings as those defined in the Announcement.

The Company would like to provide additional information on the basis for the determination of the amount of the Capital Increase.

The Board would like to clarify that the amount of the Capital Increase of RMB20 million was determined mainly based on arm’s length negotiations among all parties considering the product advantages and future development of Biosino Suzhou. The figure relating to the pre-investment valuation of Biosino Suzhou (i.e. RMB221 million) was calculated by the post-investment valuation (i.e. approximately RMB241 million, which was calculated by dividing the total amount of the Capital Increase (i.e. RMB20 million) by the interests subscribed by the Investors (i.e. 8.3%)), minus the total amount of the Capital Increase (i.e. RMB20 million). No valuation was conducted on the equity interest or assets of Biosino Suzhou.

Save as stated above, all other information set out in the Announcement remains unchanged.

For and on behalf of the Board
Biosino Bio-Technology and Science Incorporation
Wu Lebin
Chairman and Executive Director

Beijing, the PRC, 21 August 2023

As at the date of this announcement, the Board comprises:

Chairman and executive Director

Mr. Wu Lebin (吳樂斌先生)

Vice chairmen and non-executive Directors

Dr. Sun Zhe (孫哲博士) and Mr. Chen Zhengyong (陳正永先生)

President and executive Director

Mr. Chen Peng (陳鵬先生)

Non-executive Directors

Mr. Li Zhonghua (李忠華先生) and Dr. Gao Guangxia (高光俠博士)

Independent non-executive Directors

Prof. Shen Zuojun (沈佐君教授), Mr. Lu Qi (陸琪先生) and Prof. Shen Jiangan (沈劍剛教授)

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, (1) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its posting and on the website of the Company at www.zhongsheng.com.cn.